Immunotherapy Combo Effective Against Rare Non-Hodgkin Lymphoma – Specialty Pharmacy Times
|
Immunotherapy Combo Effective Against Rare Non-Hodgkin Lymphoma
Specialty Pharmacy Times AbbVie recently announced positive results from a phase 3 clinical trial investigating ibrutinib (Imbruvica) plus rituximab in patients with Waldenström's macroglobulinemia (WM), a rare non-Hodgkin lymphoma. Only 1000 to 1500 patients are diagnosed … |
